Department Metrics

• Moffitt Cancer Center Support Grant Years 24-27
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• State of Florida Appropriation
  Award Number:
  Sponsor: State of Florida
  PI:Cleveland, J.
• Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Smalley, K.
• Role of ULK3 in Sensitive and Refractory Multiple Myeloma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• Uncovering Causal Protein Markers to Improve Prostate Cancer Etiology Understanding and Risk Prediction in Africans and Europeans
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• Epigenetic mechanisms that underlie breast cancer dormancy
  Award Number:
  Sponsor: Amer Cancer Society
  PI (Contact):Gomes, A.
• SOW for project management, alliance management, and Executive Sponsors in Major Alliance with Turnstone
  Award Number:
  Sponsor: Turnstone Biologics
  PI:Cleveland, J.
• Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Marusyk, A.
• Epigenetic and Metabolic Bottlenecks of Tumorigenesis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Gomes, A.
• Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Amelio, A.
• Metabolic factors that condition breast cancer metastasis
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Gomes, A.
• Optimizing immunotherapy strategies for melanoma brain metastases
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Smalley, K.
• Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Smalley, K.
• Characterization of Plant-Based Phenolic Alkanones as Next-Generation Sun Protectants for Skin Cancer Prevention
  Award Number:
  Sponsor: US Army
  PI (Contact):Premi, S.
• Optimizing the immune mediated-destruction of NRAS mutant melanoma
  Award Number:
  Sponsor: Melanoma Research Alliance (MRA)
  PI (Contact):Smalley, K.,PI:Jaeger, A.

CLINICAL TRIAL 20386
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Condition: Thoracic
Intervention: Difluoromethylornithine (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 21626
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MK-1084 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 21630
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC
Condition: Thoracic
Intervention: Abraxane (); Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 22540
A Phase 1, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-130037, a Kelch-like ECH-associated protein 1 (KEAP1) activator, in participants with advanced solid tumors
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Taxol (paclitaxel); Taxotere (docetaxel); VVD-130037 (); docetaxel (); paclitaxel ()

CLINICAL TRIAL 22563
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma
Condition: Neurologic Oncology
Intervention: Lomustine (CeeNU); Paraplatin (carboplatin); Temodal (Temozolomide); Temozolomide (); carboplatin ()

CLINICAL TRIAL 23160
A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alisertib (MLN8237); G-CSF ()

CLINICAL TRIAL 23182
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Placebo (); V940 ()

CLINICAL TRIAL 23340
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Condition: Breast
Intervention: Alisertib (MLN8237); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 23481
Phase 2 Trial with a Safety Run-in of Combinatorial Therapies with Intrathecal (IT) Dendritic Cell Vaccines (cDC1s) inHER+ (combined with IT trastuzumab) and HER2- (combined with IT nivolumab) Breast Cancer (BC) Leptomeningeal Disease (LMD)
Condition: Neurologic Oncology
Intervention: BMS-936558 (Nivolumab); HER2 cDC1s (); HER3 cDC1s (); Herceptin (Trastuzumab); Nivolumab (Opdivo); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23582
A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemoimmunotherapy
Condition: Thoracic
Intervention: BNT327 (); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 23572
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

CLINICAL TRIAL 23579
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab); Olomorasib/Placebo (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23745
A Phase 1, First-in-Human Study of MEN2312, A KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Condition: Breast
Intervention: Capivasertib (); Elacestrant (); Faslodex (fulvestrant); MEN2312 (); everolimus (RAD001); fulvestrant ()

CLINICAL TRIAL 23772
A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); Alimta (Pemetrexed); Amivantamab (); JNJ-61186372 (Amivantamab); Osimertinib (); Paraplatin (carboplatin); Pemetrexed (); Telisotuzumab Adizutecan (); carboplatin (); cisplatin ()

CLINICAL TRIAL 23795
SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Condition: Thoracic
Intervention: ABBV-706 (); Atezolizumab (Tecentriq); Etoposide (); PM01183 (lurbinectedin); Paraplatin (carboplatin); carboplatin (); lurbinectedin ()

CLINICAL TRIAL 23805
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
Condition: Thoracic
Intervention: Datopotamab Deruxtecan (); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 23835
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)
Condition: Breast
Intervention: Herceptin (Trastuzumab); T-DM1 (); T-Dxd (); Trastuzumab (); Xeloda (capecitabine); Zanidatamab (); Zongertinib (); capecitabine (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23897
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
Condition: Thoracic
Intervention: Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Placebo (); Taxol (paclitaxel); Taxotere (docetaxel); V940 (); carboplatin (); docetaxel (); paclitaxel ()

CLINICAL TRIAL 23911
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Condition: Thoracic
Intervention: PM01183 (lurbinectedin); Tarlatamab (AMG 757); Topotecan (); ZL-1310 (); lurbinectedin ()

CLINICAL TRIAL 23918
A Phase I /II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Participants with Advanced Solid Tumors
Condition: Thoracic
Intervention: BGC515 ()

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

CLINICAL TRIAL 24003
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Rina-s ()

CLINICAL TRIAL 24096
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Condition: Breast
Intervention: 772256 (Palbociclib); Abemaciclib (); BGB-43395 (); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib ()

CLINICAL TRIAL 24104
Evaluation of a Possible Association with Skin Microbiota and Primary Cutaneous Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 24120
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC).
Condition: Thoracic
Intervention: ABBV-706 (); PM01183 (lurbinectedin); Topotecan (); lurbinectedin ()

CLINICAL TRIAL 50534
Radiation-Induced Myeloid Reprogramming in Bone Metastatic Cancer: Circulating SIRPa as Biomarkers and Therapeutic Targets
Condition: Sarcoma
Intervention:

CLINICAL TRIAL 24301
Identification and Evaluation of Immune and Targeted Therapies for Acral Melanoma
Condition: Cutaneous
Intervention:

• Srivastava S, Dawoud A, Dudley AC, Yamauchi M, Pecot CV, Amelio AL. Extracellular Matrix Remodeling in Tumors: Forces Beyond Fibroblasts. Cancer Res. 2026 Sep. Pubmedid: 42708808.
• West J, Desai B, Strobl MAR, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose-Response Convexity. Cancer Res. 2026 Sep.86(17):4434-4445. Pubmedid: 42171656. Pmcid: PMC13283037.
• Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL. Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood. 2026 Sep.148(11):1409-1422. Pubmedid: 42275255.
• Avasthi KK, Yim KH, Kim Y, Echevarria PMR, Darst LM, Abreu N, Zea KP, Hayes MT, Vosoughi A, Manley BJ, Wang L. Multiplex RT-PCR-Based Sequencing Assay to Detect Kidney Cancer-Specific Splice Variants in Tumor Tissues and Plasma Cell-Free RNAs. Mol Diagn Ther. 2026 Sep.30(5):821-832. Pubmedid: 42410176.
• Kohli M, Wang L, Tan AC, Fadlullah MZ, Shankar A, Mandrekar SJ, Haaland B. Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC). J Liq Biopsy. 2026 Sep.13:100486. Pubmedid: 42668516. Pmcid: PMC13524584.
• Xu X, Liu X, Jarajapu V, Neelature Sriramareddy S, Konecny F, Posorske B, Dollar JJ, Liu X, Jasani N, Wang K, Mecozzi N, Soto-Vargas Z, Ochoa-Rios SL, Murikipudi H, Phan N, Chadourne M, Kuznetsoff JN, Sinard J, Bennett RL, Licht JD, Smalley KSM, Harbour JW, Yu X, Karreth FA. A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer Res. 2026 Aug.86(15):3666-3686. Pubmedid: 41661679. Pmcid: PMC12974268.
• Sriramareddy S, Siddarajappa N, Park JS, Nguyen T, Kuznetsoff JN, Kurtenbach S, Dollar JJ, Adams DJ, Licht JD, Correa ZM, Chen YA, Harbour JW, Smalley KSM. GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma. Cancer Res. 2026 Aug.86(16):3968-3986. Pubmedid: 42207865. Pmcid: PMC13343499.
• Raizada D, Gomes AP. Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship. Gene Dev. 2026 Aug.40(15-16):1178-1201. Pubmedid: 42469010. Pmcid: PMC13431171.
• Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug.6(8):1647-1666. Pubmedid: 42533106. Pmcid: PMC13472910.
• Vincelette ND, Mo Q, Cheng CH, Park J, Kuykendall AT, Zhang L, Moon J, Razabdouski TN, Eksioglu EA, Lledo FM, Papenhausen PR, Xie Z, Chan O, Sallman DA, Pinilla-Ibarz J, Murphy DJ, Komrokji RS, Cleveland JL, Yu X, Yun S. Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality. medRxiv. 2026 Jul. Pubmedid: 42428085. Pmcid: PMC13345432.
• Gomez-Manzano C, Shin DH, Alvarez-Breckenridge C, Gillard AG, Morad G, Puduvalli VK, Alonso MM, Lang FF, Fueyo J. Diverse origin and nature of tumor-infiltrating lymphocytes: the infection hypothesis. J Immunother Cancer. 2026 Jul.14(7). Pubmedid: 42463282. Pmcid: PMC13384136.
• Tian Y, Wong J, McDonnell SK, Zhong H, Wu L, Larson NB, Manley BJ, Wang L. nanoASM: Long-Read Allele-Specific DNA Methylation Profiling Enables Functional Annotation of Regulatory Noncoding Variants in Human Prostate Tissues. bioRxiv. 2026 Jun. Pubmedid: 42395488. Pmcid: PMC13320949.
• Dhawan A, Marusyk A, Scott JG. Age identifies cancer drivers hidden within the genome. Nat Genetics. 2026 Jun.58(6):1201-1203. Pubmedid: 42225865.
• Thomas F, M Dujon A, Marusyk A, DeGregori J, Fontanella A, Bieuville M, Campone M, Pujol P, Alix-Panabières C, Lecam L, Roche B, Lacroix M, Hirtz C, Poulain L, Capp JP, Ujvari B, Meliani J, Noble R, Nedelcu AM, Gatenby R. When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition. NPJ Precis Oncol. 2026 Jun. Pubmedid: 42236828.
• Canevarolo RR, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, DeAvila D, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst L, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer J, Dalton W, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma. Cancer Res. 2026 Jun. Pubmedid: 42233980.
• Tagal V, Li T, Kumar R, Shrestha P, Yu X, Miroshnychenko D, Olumoyin K, Marusyk A, Davies M, Maudsley S, El-Naqa I, Gomes AP, Duckett DR, Han HS, Andor N. Ploidy shapes gemcitabine response through altered potency and delayed cell death. bioRxiv. 2026 Jun. Pubmedid: 42282758. Pmcid: PMC13251900.
• Ghali H, Al-Bzour AN, Boby A, Aflatooni S, DePalo DK, Dugan MM, Coughlin E, Mhaskar R, Tsai K, Zager JS, Sondak VK, Premi S, Storkus WJ, Messina JL, Karapetyan L. Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma. Am J Dermatopathol. 2026 Jun.48(6):439-448. Pubmedid: 41861255.
• Kuo CW, Nalla S, Sarkar S, Lee W, Wang L, Kohli M, Smith AM. Quantum Dot Encoding for In-Solution Single-Molecule Biomarker Counting in Metastatic Prostate Cancer. ACS Nano. 2026 Jun.20(22):15949-15962. Pubmedid: 42183605.
• Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Kumar P, Henry M, Marusyk V, Siqueira NSN, Gatenbee C, Ozakinci H, Bui M, Boyle TA, Scott J, Altrock PM, Pellini B, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies. Nat Commun. 2026 May.17(1). Pubmedid: 42215447. Pmcid: PMC13392419.
• Kohli M, Shankar A, Lloyd J, Wang L, Huo X, Fadlullah MZ, Tan AC, Finkelstein J. Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer. JNCI Cancer Spectr. 2026 May.10(3). Pubmedid: 42231792. Pmcid: PMC13231001.
• Kumar P, Henry M, Pelesko J, Desai B, Weh MT, Kakumanu R, Liu M, Nunes Siqueira NS, Velde RV, Marusyk V, Aurelio J, Haura E, Gray J, Pellini B, Basanta D, Marusyk A. Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLC. bioRxiv. 2026 May. Pubmedid: 42239162. Pmcid: PMC13228325.
• Smalley KSM, Levy J. Rare Melanomas: An Area of Urgent Research and Clinical Need. Pigment Cell Melanoma Res. 2026 May.39(3):e70088. Pubmedid: 42068078.
• Selvakumar S, Shetty S, Sharma AB, Zahra FT, Wang E, Koelmeyer H, Carver J, Fradley MG, Jung W, Ky B, Lefebvre B, Scherrer-Crosbie M, Wilcox NS, Wu KY, Chan O, Xie Z, Kuykendall AT, Sallman DA, Padron E, Alomar M, Cleveland JL, Mo Q, Komrokji R, Lancet JE, Yun S, Lee DH. Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia. J Am Heart Assoc. 2026 May.15(10):e048790. Pubmedid: 42089196. Pmcid: PMC13279564.
• Ozakinci H, Desai B, Kalos D, Chen DT, Henry M, Solanki H, Boyle TA, Trejo Bittar HE, Nazario GS, Haura EB, Marusyk A, Pellini B. Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRAS -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors. Transl Lung Cancer Res. 2026 Apr.15(4):94. Pubmedid: 42170277. Pmcid: PMC13186677.
• Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2026 Apr.49(4):176-187. Pubmedid: 40905435. Pmcid: PMC13011960.
• Yadav VK, Srivastava J, Venkatachalam A, Tantak MP, Lawrence NJ, Fisher DE, Lawrence HR, Premi S. Melanin-Driven Delayed CPD Formation Is Independent of Melanin Biosynthesis Pathway. J Invest Dermatol. 2026 Apr.146(4):1089-1101.e3. Pubmedid: 40992685. Pmcid: PMC12507450.
• Srivastava J, Premi S. Melanin as a Redox Hub: Linking Energy Flow to Genome Stability and Immune Control. Antioxid Redox Signal. 2026 Apr.44(10-12):618-635. Pubmedid: 41680087. Pmcid: PMC12952693.
• Halbers LP, Brennan CK, Scipioni L, Tedeschi G, Torrey ZR, Parag-Sharma K, Labra B, Gohlke C, Amelio AL, Digman MA, Prescher JA. Expanded applications of bioluminescence microscopy with phasor analysis. Cell Rep Methods. 2026 Apr.6(4):101344. Pubmedid: 41916304. Pmcid: PMC13106971.
• Hamaidi I, Cheng P, Jun SY, Manna A, Wang MH, Nguyen A, Can I, Zhang MG, Taylor OO, Bailon LUL, Fang B, Perez B, Creelan BC, Marusyk A, Shin D, Hwang TH, Berglund AE, Shapiro VS, Ji HM, Conejo-Garcia JR, Kim S. SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling. Nat Immunol. 2026 Feb.27(2):213-224. Pubmedid: 41611868. Pmcid: PMC12864039.
• Nasr MM, Wadie B, Li T, Frieling JS, du Bois H, Bishop RT, Tauro M, Malik B, Nyman KJ, Lynch CC. PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. Cancer Res. 2026 Feb.86(3):604-621. Pubmedid: 41105683. Pmcid: PMC12862344.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
• Tian Y, McDonnell SK, Wu L, Larson NB, Wang L. Fine mapping regulatory variants by characterizing native CpG methylation with nanopore long-read sequencing. HGG Adv. 2026 Jan.7(1):100532. Pubmedid: 41109954. Pmcid: PMC12642126.
• Solanki HS, Shah H, Imbody D, Desai B, Kato R, Miroshnychenko D, Stern YE, Majumder A, Sarcar B, Xieraili A, Stewart PA, Fang B, Zhang Y, Yao J, Darville LN, Koomen JM, Rix U, Evans JW, Yang YC, Ahler E, Marusyk A, Singh M, Aronchik I, Haura EB. RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. Cancer Res. 2026 Jan.86(2):467-484. Pubmedid: 41165456. Pmcid: PMC12962340.
• Anastacio Da Costa Carvalho L, Tovbis Shifrin N, Phadke MS, Emmons MF, Pechuan-Jorge X, Mbuga F, Ospina OE, Chow C, Seu L, Rose OL, Hegde A, Khushalani NI, Quintana E, Smalley KSM. RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer Immunol Res. 2026 Jan.14(1):90-106. Pubmedid: 41186497. Pmcid: PMC12666865.
• Avasthi KK, Manley BJ, Pellini B, Zhang J, Bloomer AM, Jean-Baptiste E, Marchion DC, Fang B, Koomen JM, Siegel EM, Wang L. Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer. BMC Cancer. 2025 Dec.26(1):160. Pubmedid: 41469584. Pmcid: PMC12859987.
• Zhong H, Zhu J, Liu S, Wu C, Wang L, Whelton SP, Marshall CH, Blaha MJ, Durda P, Guo X, Johnson CW, Lin HJ, Taylor KD, Tracy RP, Yarden RI, Manichaikul AW, Rich SS, Rotter JI, Deo R, Dubin RF, Ganz P, Wu L. Proteome-wide association study of prostate cancer risk across populations. Nat Commun. 2025 Dec. Pubmedid: 41353205.
• Xu W, Zhang Q, Qiao L, Wang Z, Wang T, Dong D, Zhang Q, Wang L, Wei GH, Zhang P. IP-SNPs-seq links noncoding risk alleles to lineage transcription factor programs in prostate cancer. Cell Mol Life Sci. 2025 Dec.82(1):438. Pubmedid: 41359169. Pmcid: PMC12686227.
• Yadav VK, Fang B, Koomen JM, Srivastava J, Premi S. Quantitative Proteomics of Nitrosylated Proteins in Melanoma Using the Biotin-Switch Technique Combined With Tandem Mass Tag Labeling. Bio Protoc. 2025 Dec.15(23):e5535. Pubmedid: 41377102. Pmcid: PMC12689159.
• Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Gutowski R, Fadlullah MZH, Finkelstein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L. Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol. 2025 Dec.10(1):29. Pubmedid: 41390880. Pmcid: PMC12816654.
• Hu Q, Remsing Rix LL, Desai B, Miroshnychenko D, Li X, Welsh EA, Fang B, Wright GM, Chaudhary N, Kroeger JL, Doebele RC, Koomen JM, Haura EB, Marusyk A, Rix U. Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling. Sci Signal. 2025 Dec.18(918):eads7662. Pubmedid: 41433419.
• Morales MFG, Hogue SR, Pitcher S, Jeong D, Radosavljevic I, Stefanou A, Felder SI, Burns JR, Dowd SE, Vogtmann E, Sinha R, Wang L, Wang X, Permuth JB, Sears CL, Andersen SW, Greathouse KL, Kresovich JK, Friedman MS, Siegel EM, Byrd DA. Survival implications of the age-associated tumor and normal adjacent tissue microbiome among colorectal cancer patients. Gut Pathog. 2025 Dec.17(1):109. Pubmedid: 41437389. Pmcid: PMC12739855.
• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• Sultan M, Ma S, Diez J, Velayutham S, Al-Harbi Y, Choi JY, Smalley KSM, Nathanson L, Beljanski V, Minond D. Modulation of Spliceosomal Proteins hnRNPH1 and H2 Increases Melanoma Cell Pro-Inflammatory Signaling In Vitro. Biomolecules. 2025 Nov.15(11). Pubmedid: 41301529. Pmcid: PMC12649858.
• Drapela S, Rad RC, Ilter D, Gomes AP. Protocol for the utilization of murine interstitial fluid extract to model breast cancer in the context of old age in vitro. STAR Protoc. 2025 Oct.6(4):104178. Pubmedid: 41171756. Pmcid: PMC12642106.
• Dong D, Wang Z, Liu M, Zhang Q, Xu W, Wei Y, Zhu J, Yang X, Zhang Q, Zhu Y, Wang L, Zhang P, Wei GH. Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus. Nat Commun. 2025 Oct.16(1):8950. Pubmedid: 41062477. Pmcid: PMC12508145.
• Lazure F, Gomes AP. Cancer progression through the lens of age-induced metabolic reprogramming. Nat Rev Cancer. 2025 Oct.25(10):801-817. Pubmedid: 40646271.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Beck R, Tagal V, Amin S, Bakhoum SF, Maley C, Verhaak RGW, Gomes AP, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Lett. 2025 Oct.630:217878. Pubmedid: 40517938.
• West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.